Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 34 n° 316

Almirall announced that a key milestone under the collaboration with Nuevolution has been achieved

Posted by fidest press agency su lunedì, 4 marzo 2019

The strategic collaboration was entered on December 12, 2016 with the aim to develop innovative RORγt inhibitors with best-in-class potential for the oral and topical treatment of Dermatology diseases and Psoriatic Arthritis.A significant part of the collaboration work has been to evaluate preclinical safety parameters of RORγt inhibition and to comprehensively de-risk the program prior to any human testing. The milestone data achieved supports a program with a Candidate Drug (CD) having best-in-class potential.The program continues its progression towards clinical development. The positive result triggered a contractual milestone to Nuevolution.Bhushan Hardas, M.D., MBA, Chief Scientific Officer of Almirall, commented “we are very pleased with the progress achieved in our strategic collaboration with Nuevolution, which reflects Almirall’s commitment to becoming a leader in medical dermatology by reinforcing our pipeline with true innovative best in class solutions”.Alex H. Gouliaev, Ph.D., Chief Executive Officer of Nuevolution, commented: “this underscores the positive opportunities for this very unique program. The program development has benefitted significantly from much synergy between and dedication by the teams”.Almirall had one of the highest levels of R&D investments in the Spanish Pharmaceutical Industry in 2018, representing over 12% of Net Sales (€88 MM). In addition, Almirall invests in assets, strategic partnerships and collaborations in research. For more information, please visit


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: